{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:03:36Z","timestamp":1793714616646,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Scientific Research Foundation of Heilongjiang University of Chinese Medicine","award":["2019MS17"],"award-info":[{"award-number":["2019MS17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04117-1","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T06:46:04Z","timestamp":1754549164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic value of ALBI score for all-cause mortality in metabolic associated fatty liver disease patients: a cohort study from NHANES 2003\u20132018"],"prefix":"10.1186","volume":"25","author":[{"given":"Guoxing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baozhu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"4117_CR1","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review and meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res. 2024;55:103043.","journal-title":"Arch Med Res"},{"issue":"Suppl 1","key":"4117_CR2","first-page":"S17","volume":"28","author":"C Gofton","year":"2022","unstructured":"Gofton C, Upendran Y, Zheng MH, et al. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2022;28(Suppl 1):S17\u201331.","journal-title":"Clin Mol Hepatol"},{"key":"4117_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.cmet.2023.06.012","volume":"35","author":"JM Paik","year":"2023","unstructured":"Paik JM, Henry L, Younossi ZM. Nonalcoholic fatty liver disease mortality May not be decreasing: a need for careful interpretation of GBD 2019 estimates of liver deaths. Cell Metab. 2023;35:1087\u20138.","journal-title":"Cell Metab"},{"key":"4117_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jgr.2020.11.002","volume":"45","author":"SJ Yoon","year":"2021","unstructured":"Yoon SJ, Kim SK, Lee NY, et al. Effect of Korean red ginseng on metabolic syndrome. J Ginseng Res. 2021;45:380\u20139.","journal-title":"J Ginseng Res"},{"key":"4117_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13679-019-00357-x","volume":"8","author":"P Weihe","year":"2019","unstructured":"Weihe P, Weihrauch-Bl\u00fcher S. Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives. Curr Obes Rep. 2019;8:472\u20139.","journal-title":"Curr Obes Rep"},{"key":"4117_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14218\/JCTH.2019.00028","volume":"7","author":"DH Akhtar","year":"2019","unstructured":"Akhtar DH, Iqbal U, Vazquez-Montesino LM, et al. Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2019;7:362\u201370.","journal-title":"J Clin Transl Hepatol"},{"key":"4117_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4093\/dmj.2020.0039","volume":"45","author":"F Li","year":"2021","unstructured":"Li F, Ye J, Sun Y, et al. Distinct dose-dependent association of free fatty acids with diabetes development in nonalcoholic fatty liver disease patients. Diabetes Metab J. 2021;45:417\u201329.","journal-title":"Diabetes Metab J"},{"key":"4117_CR8","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Castera L, Wong VW-S. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21:2026\u201339.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4117_CR9","doi-asserted-by":"publisher","first-page":"e231007","DOI":"10.1148\/radiol.231007","volume":"309","author":"T Xia","year":"2023","unstructured":"Xia T, Du M, Li H, et al. Association between liver MRI proton density fat fraction and liver disease risk. Radiology. 2023;309:e231007.","journal-title":"Radiology"},{"key":"4117_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jare.2024.03.004","volume":"68","author":"H Li","year":"2025","unstructured":"Li H, Liang J, Han M, et al. Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: a review. J Adv Res. 2025;68:43\u201362.","journal-title":"J Adv Res"},{"key":"4117_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/biom15010140","volume":"15","author":"X Wan","year":"2025","unstructured":"Wan X, Ma J, Bai H, et al. Drug advances in NAFLD: individual and combination treatment strategies of natural products and small-synthetic-molecule drugs. Biomolecules. 2025;15:140.","journal-title":"Biomolecules"},{"key":"4117_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"4117_CR13","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"4117_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1159\/000508971","volume":"9","author":"K Kariyama","year":"2020","unstructured":"Kariyama K, Nouso K, Hiraoka A, et al. EZ-ALBI score for predicting hepatocellular carcinoma prognosis. Liver Cancer. 2020;9:734\u201343.","journal-title":"Liver Cancer"},{"key":"4117_CR15","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.jhepr.2022.100557","volume":"4","author":"H Toyoda","year":"2022","unstructured":"Toyoda H, Johnson PJ. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022;4:100557.","journal-title":"JHEP Rep"},{"key":"4117_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3748\/wjg.v30.i9.999","volume":"30","author":"SX Xu","year":"2024","unstructured":"Xu SX, Yang F, Ge N, et al. Role of albumin-bilirubin score in non-malignant liver disease. World J Gastroenterol. 2024;30:999\u20131004.","journal-title":"World J Gastroenterol"},{"key":"4117_CR17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s00261-024-04324-6","volume":"49","author":"U Eryuruk","year":"2024","unstructured":"Eryuruk U, Tasdemir MN, Karasu HI, et al. Comparison of the efficacy of the Gadoxetic acid MRI-derived relative enhancement index and functional liver imaging score in predicting liver function: validation with albumin-bilirubin grade. Abdom Radiol (NY). 2024;49:1456\u201366.","journal-title":"Abdom Radiol (NY)"},{"key":"4117_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000452846","volume":"6","author":"A Hiraoka","year":"2017","unstructured":"Hiraoka A, Kumada T, Kudo M, et al. Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and Child-Pugh classifications. Liver Cancer. 2017;6:204\u201315.","journal-title":"Liver Cancer"},{"key":"4117_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/jgh.13250","volume":"31","author":"A Hiraoka","year":"2016","unstructured":"Hiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1031\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"4117_CR20","doi-asserted-by":"publisher","first-page":"e0399","DOI":"10.1097\/HC9.0000000000000399","volume":"8","author":"F Li","year":"2024","unstructured":"Li F, Guan Z, Gao Y, et al. ER stress promotes mitochondrial calcium overload and activates the ROS\/NLRP3 axis to mediate fatty liver ischemic injury. Hepatol Commun. 2024;8:e0399.","journal-title":"Hepatol Commun"},{"key":"4117_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","volume":"67","author":"SH Ibrahim","year":"2018","unstructured":"Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut. 2018;67:963\u201372.","journal-title":"Gut"},{"key":"4117_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2015.05.014","volume":"412","author":"X Shen","year":"2015","unstructured":"Shen X, Yang L, Yan S, et al. Fetuin A promotes lipotoxicity in \u03b2 cells through the TLR4 signaling pathway and the role of Pioglitazone in anti-lipotoxicity. Mol Cell Endocrinol. 2015;412:1\u201311.","journal-title":"Mol Cell Endocrinol"},{"key":"4117_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol"},{"key":"4117_CR24","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1016\/j.cgh.2021.12.015","volume":"20","author":"P Golabi","year":"2022","unstructured":"Golabi P, Paik JM, Harring M, et al. Prevalence of high and moderate risk nonalcoholic fatty liver disease among adults in the united states, 1999\u20132016. Clin Gastroenterol Hepatol. 2022;20:2838\u201347.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4117_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","volume":"69","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69:564\u20138.","journal-title":"Gut"},{"key":"4117_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/atm.2020.02.114","volume":"8","author":"Z Wang","year":"2020","unstructured":"Wang Z, Fan Q, Wang M, et al. Comparison between Child-Pugh score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and Sorafenib for hepatocellular carcinoma. Ann Transl Med. 2020;8:537.","journal-title":"Ann Transl Med"},{"key":"4117_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000529996","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Cheng AL, et al. Albumin-bilirubin grade analyses of Atezolizumab plus bevacizumab versus Sorafenib in patients with unresectable hepatocellular carcinoma: a post hoc analysis of the phase III IMbrave150 study. Liver Cancer. 2023;12:479\u201393.","journal-title":"Liver Cancer"},{"key":"4117_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/bjc.2016.33","volume":"114","author":"H Toyoda","year":"2016","unstructured":"Toyoda H, Lai PBS, O\u2019Beirne J, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer. 2016;114:744\u201350.","journal-title":"Br J Cancer"},{"key":"4117_CR29","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1002\/hep4.2072","volume":"6","author":"M Reincke","year":"2022","unstructured":"Reincke M, Schultheiss M, Doppler M, et al. Hepatic decompensation after transarterial radioembolization: a retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun. 2022;6:3223\u201333.","journal-title":"Hepatol Commun"},{"key":"4117_CR30","first-page":"610","volume":"13","author":"KP Kim","year":"2024","unstructured":"Kim KP, Kim KM, Ryoo BY, et al. Prognostic efficacy of the albumin-bilirubin score and treatment outcomes in hepatocellular carcinoma: a large-scale, multicenter real-world database study. Liver Cancer. 2024;13:610\u201328.","journal-title":"Liver Cancer"},{"key":"4117_CR31","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1248\/bpb.b23-00469","volume":"46","author":"H Ooi","year":"2023","unstructured":"Ooi H, Asai Y, Koriyama Y, et al. Effect of ceftriaxone dosage and albumin-bilirubin score on the risk of ceftriaxone-induced liver injury. Biol Pharm Bull. 2023;46:1731\u20136.","journal-title":"Biol Pharm Bull"},{"key":"4117_CR32","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.1038\/s41598-019-47687-3","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhong GC, Tan HY, et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep. 2019;9:11124.","journal-title":"Sci Rep"},{"key":"4117_CR33","doi-asserted-by":"crossref","unstructured":"Semeya AA, Elgamal R, Othman AAA. Correlation of serum zinc levels with hepatic encephalopathy severity in patients with decompensated liver cirrhosis: a prospective observational study from Egypt. Biol Trace Elem Res. 2025;208.","DOI":"10.1007\/s12011-025-04544-x"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04117-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04117-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:29:20Z","timestamp":1757370560000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04117-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04117-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the CDC Institutional Review Board, and the study was conducted in accordance with the Declaration of Helsinki and relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"561"}}